{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:08:52Z","timestamp":1789178932710,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Application research of Flow Cytometric Fluorescence Immunoassay for the Detection of Cytokines in Patients with Malignant Hematologic Disorders and Infections","award":["20221410"],"award-info":[{"award-number":["20221410"]}]},{"name":"Hengrui Hebei Innovative Development Medical Collaboration Program","award":["HR202502081"],"award-info":[{"award-number":["HR202502081"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00164-z","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:12:28Z","timestamp":1789132348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Limited evidence for causal effects of circulating inflammatory cytokines on the risk of selected hematologic malignancies: a two-sample Mendelian randomization study"],"prefix":"10.1007","volume":"61","author":[{"given":"Huimin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"1","key":"164_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","volume":"8","author":"A Zhao","year":"2023","unstructured":"Zhao A, et al. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduct Target Ther. 2023;8(1):71.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"164_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","volume":"130","author":"J Taylor","year":"2017","unstructured":"Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017;130(4):410\u201323.","journal-title":"Blood"},{"key":"164_CR3","doi-asserted-by":"crossref","unstructured":"Auberger P, Tamburini-Bonnefoy J, Puissant A. Drug Resistance in Hematological Malignancies. Int J Mol Sci. 2020;21(17).","DOI":"10.3390\/ijms21176091"},{"key":"164_CR4","doi-asserted-by":"publisher","first-page":"204062072311682","DOI":"10.1177\/20406207231168211","volume":"14","author":"LC Saiz","year":"2023","unstructured":"Saiz LC, et al. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies. Ther Adv Hematol. 2023;14:20406207231168212.","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"164_CR5","first-page":"Cd013365","volume":"9","author":"M Ernst","year":"2021","unstructured":"Ernst M, et al. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021;9(9):Cd013365.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"164_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/joim.13697","volume":"294","author":"R Rosenquist","year":"2023","unstructured":"Rosenquist R, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. J Intern Med. 2023;294(4):413\u201336.","journal-title":"J Intern Med"},{"issue":"8","key":"164_CR7","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/bloodadvances.2019001317","volume":"4","author":"A Sitlinger","year":"2020","unstructured":"Sitlinger A, Brander DM, Bartlett DB. Impact of exercise on the immune system and outcomes in hematologic malignancies. Blood Adv. 2020;4(8):1801\u201311.","journal-title":"Blood Adv"},{"issue":"6","key":"164_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ajh.26529","volume":"97","author":"I Demel","year":"2022","unstructured":"Demel I, et al. Natural killer cells: innate immune system as a part of adaptive immunotherapy in hematological malignancies. Am J Hematol. 2022;97(6):802\u201317.","journal-title":"Am J Hematol"},{"key":"164_CR9","doi-asserted-by":"crossref","unstructured":"Baumeister J, et al. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives. Cells. 2021;10(12):3551.","DOI":"10.3390\/cells10123551"},{"issue":"10","key":"164_CR10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356\u201363.","journal-title":"J Clin Oncol"},{"issue":"24","key":"164_CR11","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","volume":"118","author":"AG Fleischman","year":"2011","unstructured":"Fleischman AG, et al. TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392\u20138.","journal-title":"Blood"},{"issue":"1\u20132","key":"164_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/10428199809058383","volume":"29","author":"H Kato","year":"1998","unstructured":"Kato H, et al. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin\u2019s lymphoma. Leuk Lymphoma. 1998;29(1\u20132):71\u20139.","journal-title":"Leuk Lymphoma"},{"key":"164_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ebiom.2019.02.048","volume":"41","author":"H Zhong","year":"2019","unstructured":"Zhong H, et al. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin\u2019s lymphoma. EBioMedicine. 2019;41:167\u201374.","journal-title":"EBioMedicine"},{"issue":"9","key":"164_CR14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1089\/gtmb.2016.0036","volume":"20","author":"AF Nursal","year":"2016","unstructured":"Nursal AF, et al. The associations of IL-6, IFN-\u03b3, TNF-\u03b1, IL-10, and TGF-\u03b21 functional variants with acute myeloid leukemia in Turkish patients. Genet Test Mol Biomarkers. 2016;20(9):544\u201351.","journal-title":"Genet Test Mol Biomarkers"},{"key":"164_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cytogfr.2018.08.004","volume":"43","author":"S Binder","year":"2018","unstructured":"Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 2018;43:8\u201315.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"164_CR16","doi-asserted-by":"publisher","first-page":"e64158","DOI":"10.1371\/journal.pone.0064158","volume":"8","author":"YJ Li","year":"2013","unstructured":"Li YJ, et al. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer\/T-cell lymphoma, nasal type. PLoS ONE. 2013;8(5):e64158.","journal-title":"PLoS ONE"},{"issue":"1","key":"164_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12185-022-03321-z","volume":"116","author":"H Yanagisawa","year":"2022","unstructured":"Yanagisawa H, et al. Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes. Int J Hematol. 2022;116(1):81\u20138.","journal-title":"Int J Hematol"},{"issue":"2","key":"164_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/10428194.2018.1482540","volume":"60","author":"W Qin","year":"2019","unstructured":"Qin W, et al. Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis. Leuk Lymphoma. 2019;60(2):358\u201366.","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"164_CR19","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318(19):1925\u20136.","journal-title":"JAMA"},{"issue":"6","key":"164_CR20","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ije\/dyx028","volume":"45","author":"FP Hartwig","year":"2016","unstructured":"Hartwig FP, et al. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2016;45(6):1717\u201326.","journal-title":"Int J Epidemiol"},{"key":"164_CR21","doi-asserted-by":"crossref","unstructured":"Sanderson E, et al. Mendelian randomization. Nat Rev Methods Primers. 2022;2.","DOI":"10.1038\/s43586-021-00092-5"},{"issue":"11","key":"164_CR22","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/acr.25400","volume":"76","author":"K Nguyen","year":"2024","unstructured":"Nguyen K, Mitchell BD. A guide to understanding Mendelian randomization studies. Arthritis Care Res (Hoboken). 2024;76(11):1451\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"164_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s101620010052","volume":"2","author":"JK Moore","year":"2001","unstructured":"Moore JK, Guan YL. Cytoarchitectural and axonal maturation in human auditory cortex. J Assoc Res Otolaryngol. 2001;2(4):297\u2013311.","journal-title":"J Assoc Res Otolaryngol"},{"key":"164_CR24","doi-asserted-by":"crossref","unstructured":"Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. Cold Spring Harb Perspect Med. 2022;12(1):a040501.","DOI":"10.1101\/cshperspect.a040501"},{"issue":"1","key":"164_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ajhg.2016.11.007","volume":"100","author":"AV Ahola-Olli","year":"2017","unstructured":"Ahola-Olli AV, et al. Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. Am J Hum Genet. 2017;100(1):40\u201350.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"164_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ajhg.2018.09.009","volume":"103","author":"S Ligthart","year":"2018","unstructured":"Ligthart S, et al. Genome analyses of >200,000 individuals identify 58 loci for chronic inflammation and highlight pathways that link inflammation and complex disorders. Am J Hum Genet. 2018;103(5):691\u2013706.","journal-title":"Am J Hum Genet"},{"issue":"7831","key":"164_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","volume":"586","author":"EL Bao","year":"2020","unstructured":"Bao EL, et al. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. Nature. 2020;586(7831):769\u201375.","journal-title":"Nature"},{"issue":"11","key":"164_CR28","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/sim.6835","volume":"35","author":"S Burgess","year":"2016","unstructured":"Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2016;35(11):1880\u2013906.","journal-title":"Stat Med"},{"issue":"5","key":"164_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377\u201389.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"164_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304\u201314.","journal-title":"Genet Epidemiol"},{"issue":"1","key":"164_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12916-020-01778-5","volume":"18","author":"F Wu","year":"2020","unstructured":"Wu F, et al. Mendelian randomization study of inflammatory bowel disease and bone mineral density. BMC Med. 2020;18(1):312.","journal-title":"BMC Med"},{"issue":"6","key":"164_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/gepi.22207","volume":"43","author":"JS Ong","year":"2019","unstructured":"Ong JS, MacGregor S. Implementing MR-PRESSO and GCTA-GSMR for pleiotropy assessment in Mendelian randomization studies from a practitioner\u2019s perspective. Genet Epidemiol. 2019;43(6):609\u201316.","journal-title":"Genet Epidemiol"},{"issue":"1","key":"164_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s12967-022-03691-2","volume":"20","author":"G Xiao","year":"2022","unstructured":"Xiao G, et al. Causality of genetically determined metabolites on anxiety disorders: a two-sample Mendelian randomization study. J Transl Med. 2022;20(1):475.","journal-title":"J Transl Med"},{"issue":"5","key":"164_CR34","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/ije\/dyt179","volume":"42","author":"MJ Brion","year":"2013","unstructured":"Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5):1497\u2013501.","journal-title":"Int J Epidemiol"},{"key":"164_CR35","doi-asserted-by":"publisher","first-page":"1347402","DOI":"10.3389\/fonc.2024.1347402","volume":"14","author":"S Saluja","year":"2024","unstructured":"Saluja S, et al. Inflammation as a driver of hematological malignancies. Front Oncol. 2024;14:1347402.","journal-title":"Front Oncol"},{"key":"164_CR36","doi-asserted-by":"crossref","unstructured":"Craver BM, et al. The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. Cancers (Basel). 2018;10(4):104.","DOI":"10.3390\/cancers10040104"},{"key":"164_CR37","doi-asserted-by":"publisher","first-page":"772408","DOI":"10.3389\/fimmu.2021.772408","volume":"12","author":"V Camacho","year":"2021","unstructured":"Camacho V, Kuznetsova V, Welner RS. Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front Immunol. 2021;12:772408.","journal-title":"Front Immunol"},{"issue":"7","key":"164_CR38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","volume":"129","author":"C Korn","year":"2017","unstructured":"Korn C, M\u00e9ndez-Ferrer S. Myeloid malignancies and the microenvironment. Blood. 2017;129(7):811\u201322.","journal-title":"Blood"},{"key":"164_CR39","doi-asserted-by":"publisher","first-page":"683401","DOI":"10.3389\/fimmu.2021.683401","volume":"12","author":"DAC Fisher","year":"2021","unstructured":"Fisher DAC, et al. Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol. 2021;12:683401.","journal-title":"Front Immunol"},{"issue":"3","key":"164_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","volume":"14","author":"LF Mendez Luque","year":"2019","unstructured":"Mendez Luque LF, et al. Key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression, and symptoms. Curr Hematol Malig Rep. 2019;14(3):145\u201353.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"164_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41375-018-0203-0","volume":"33","author":"S Niyongere","year":"2019","unstructured":"Niyongere S, et al. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019;33(1):205\u201316.","journal-title":"Leukemia"},{"issue":"4","key":"164_CR42","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/leu.2011.251","volume":"26","author":"A Pardanani","year":"2012","unstructured":"Pardanani A, et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia. 2012;26(4):693\u20139.","journal-title":"Leukemia"},{"issue":"5","key":"164_CR43","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.3390\/cimb45050251","volume":"45","author":"MS Moawadh","year":"2023","unstructured":"Moawadh MS, et al. Molecular Evaluation of the Impact of Polymorphic Variants in Apoptotic (Bcl-2\/Bax) and Proinflammatory Cytokine (TNF-\u03b1\/IL-8) Genes on the Susceptibility and Progression of Myeloproliferative Neoplasms: A Case-Control Biomarker Study. Curr Issues Mol Biol. 2023;45(5):3933\u201352.","journal-title":"Curr Issues Mol Biol"},{"key":"164_CR44","doi-asserted-by":"publisher","first-page":"886144","DOI":"10.3389\/fimmu.2022.886144","volume":"13","author":"J Song","year":"2022","unstructured":"Song J, et al. Genetically predicted circulating levels of cytokines and the risk of cancer. Front Immunol. 2022;13:886144.","journal-title":"Front Immunol"},{"issue":"3","key":"164_CR45","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3324\/haematol.2019.236513","volume":"106","author":"GI Gavriilidis","year":"2021","unstructured":"Gavriilidis GI, et al. Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia. Haematologica. 2021;106(3):692\u2013700.","journal-title":"Haematologica"},{"issue":"4","key":"164_CR46","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.V90.4.1345","volume":"90","author":"VC Broudy","year":"1997","unstructured":"Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90(4):1345\u201364.","journal-title":"Blood"},{"issue":"R1","key":"164_CR47","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-98.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"164_CR48","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s12885-024-12301-x","volume":"24","author":"H Xiong","year":"2024","unstructured":"Xiong H, et al. Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study. BMC Cancer. 2024;24(1):531.","journal-title":"BMC Cancer"},{"issue":"9","key":"164_CR49","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1182\/bloodadvances.2023012246","volume":"8","author":"P Jiang","year":"2024","unstructured":"Jiang P, et al. Dissecting causal links between gut microbiota, inflammatory cytokines, and DLBCL: a Mendelian randomization study. Blood Adv. 2024;8(9):2268\u201378.","journal-title":"Blood Adv"},{"issue":"1","key":"164_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s44178-025-00155-7","volume":"4","author":"Y Tang","year":"2025","unstructured":"Tang Y, et al. Exploring the causal relationship between inflammatory cytokines and intrahepatic cholangiocarcinoma: a Mendelian randomization study. Holistic Integrative Oncology. 2025;4(1):19.","journal-title":"Holistic Integrative Oncology"},{"issue":"7","key":"164_CR51","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc1388","volume":"4","author":"F Balkwill","year":"2004","unstructured":"Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"164_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"164_CR53","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","volume":"92","author":"J Lennartsson","year":"2012","unstructured":"Lennartsson J, R\u00f6nnstrand L. Stem cell factor receptor\/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92(4):1619\u201349.","journal-title":"Physiol Rev"},{"issue":"2","key":"164_CR54","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512\u201325.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"164_CR55","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"164_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41572-021-00319-5","volume":"7","author":"JM Connors","year":"2021","unstructured":"Connors JM, et al. Author correction: Hodgkin lymphoma. Nat Rev Dis Primers. 2021;7(1):79.","journal-title":"Nat Rev Dis Primers"},{"key":"164_CR57","doi-asserted-by":"crossref","unstructured":"Alaggio R, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748.","DOI":"10.1038\/s41375-022-01620-2"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00164-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00164-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00164-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:02:11Z","timestamp":1789178531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00164-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00164-z","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participants","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"53"}}